

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
01 February 2024 (01.02.2024)



(10) International Publication Number
WO 2024/026122 A3

(51) International Patent Classification:

C07H 21/02 (2006.01) A61P 25/08 (2006.01)
A61K 31/7088 (2006.01)

(21) International Application Number:

PCT/US2023/029040

(22) International Filing Date:

28 July 2023 (28.07.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/369,845 29 July 2022 (29.07.2022) US

(71) Applicant: **STOKE THERAPEUTICS, INC.** [US/US];
45 Wiggins Avenue, Bedford, Massachusetts 01730 (US).

(72) Inventors: **AZNAREZ, Isabel**; c/o Stoke Therapeutics, Inc., 45 Wiggins Avenue, Bedford, Massachusetts 01730 (US). **HAN, Zhou**; c/o Stoke Therapeutics, Inc., 45 Wiggins Avenue, Bedford, Massachusetts 01730 (US). **CHRISTIANSEN, Anne**; c/o Stoke Therapeutics, Inc., 45 Wiggins Avenue, Bedford, Massachusetts 01730 (US). **MEENA, Meena**; c/o Stoke Therapeutics, Inc., 45 Wiggins Avenue, Bedford, Massachusetts 01730 (US). **TICHO, Baruch**; c/o Stoke Therapeutics, Inc., 45 Wiggins Avenue, Bedford, Massachusetts 01730 (US). **LIAU, Gene**; c/o

o Stoke Therapeutics, Inc., 45 Wiggins Avenue, Bedford, Massachusetts 01730 (US).

(74) Agent: **CHANDRAMOULI, Srividya**; Wilson Sonsini Goodrich & Rosati, 650 Page Mill Road, Palo Alto, California 94304 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,

(54) Title: COMPOUNDS FOR TREATMENT OF CONDITIONS AND DISEASES




FIG. 1C

(57) Abstract: Compounds are provided herein that can promote expression of a specific gene, *SCN1A*. In some aspects, provided herein are compositions, methods, and kits relating to the compounds disclosed herein. In some aspects, compounds provided herein can target the alternative splicing events in *SCN1A* gene and can modulate the expression level of functional proteins in Dravet Syndrome patients and/or inhibit aberrant protein expression. Such compounds can be used to treat a condition caused by *SCN1A*, *SCN8A* or *SCN5A* protein deficiency.

[Continued on next page]

SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

(88) Date of publication of the international search report:

28 March 2024 (28.03.2024)